Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous MUC1-activated T-cells
- Development stage
- Phase 1
- Lead developer
- Mayo Clinic
- Modality
- Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous MUC1-activated T-cells are a form of adoptive cell therapy in which a patient's own (autologous) peripheral blood-derived T lymphocytes are collected and then activated or stimulated ex vivo to recognize the tumor-associated antigen mucin 1 (MUC1). After expansion and activation, these cells are reinfused into the patient. The goal is for these engineered or stimulated T-cells to specifically recognize and induce cytotoxicity against tumor cells expressing the aberrant or overexpressed form of MUC1, which is common in various cancers such as ovarian cancer, breast cancer, multiple myeloma, colon cancer, and others. This approach leverages the immune system's ability to target malignant cells while sparing normal tissues. The therapy is being investigated primarily for relapsed/refractory cancers that express high levels of MUC1[3][4][5][6].
- Other names
- MUC1-activated T cellsMUC-1-activated T cellsMUC 1-activated T cellsautologous MUC1-stimulated T cellsin-house manufactured MUC1-activated T cells
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on autologous MUC1-activated T-cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous MUC1-activated T-cells.